Developer docs
API playgroundTry for free, no card

Search company profiles

Phylos

Full company profile

uuid0002k39

Namestring
Phylos
Legal namestring
Phylos Bioscience, Inc.
Websiteurl
phylos.bio
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Phylos Bioscience is a Portland, Oregon-based cannabis and hemp genetics company founded in 2014 that develops F1 hybrid seeds, rare cannabinoid (THCV) genetics, and genomic tools for commercial cultivators, extraction operators, consumer brands, and home growers. The company's core product is its Production-Ready Seed platform — fully-feminized, phenotypically stable F1 hybrid lines developed through marker-assisted selection and supported by an Illumina-partnered genotyping array that generates 50,000+ data points per plant. Phylos also operates the Phylos Galaxy, a 3D visualization tool containing genetic samples from 80+ countries mapped to six sub-populations, and a parallel rare-cannabinoid program anchored by the Natural Natural brand (THCV-dominant varieties GSD, Joyride, Powerhouse) with efficacy validated by an IRB-approved People Science clinical study.

The company monetizes through four primary revenue streams: direct and channel-based seed sales (commercial cultivators via enterprise sales plus home growers through an exclusive ILGM partnership), licensing of rare cannabinoid genetics to consumer brands, variety licensing for in-licensed genetics, and the Innovation Partner Program providing strategic operators like Organigram Global with priority access to the genetics pipeline and territorial exclusivity in Canada, Australia, UK, Germany, and Israel. Total committed capital includes $10M in senior secured convertible loans from Organigram (maturity May 2028), a $7.6M 2022 round led by Merida Capital Holdings with Accomplice and Entourage Effect Capital, and a 2024 SEC exempt offering of up to $4M. Pricing is not publicly disclosed; commercial seed pricing is quote-based while consumer sales flow through e-commerce at seeds.phylos.bio.

Phylos serves commercial cannabis cultivators, licensed hemp growers, extraction companies, and home growers across more than 10 U.S. states and five international markets. The company employs 51-100 staff including geneticists, breeders, and data scientists, operates an 80,000 ft² R&D glasshouse facility in partnership with Progressive Plant Research (a jointly controlled subsidiary), and has published proprietary genetic markers for stress tolerance, hermaphroditism resistance, autoflowering behavior (PRR37/PRR3 locus on chromosome 1), and washability (markers on chromosomes 6 and 7) — establishing a defensible position at the intersection of seed genetics and computational genomics for cannabis.

Short descriptiontext

Phylos Bioscience is a Portland-based cannabis and hemp genetics company founded in 2014 that develops F1 hybrid seeds, rare cannabinoid (THCV) genetics, and genomic tools for commercial cultivators, extraction brands, consumer product companies, and home growers. Revenue is generated through seed sales, branded ingredient licensing, and strategic Innovation Partner agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPortland, United States
HQ citystring
Portland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabis seed genetics, f1 hybrid seeds, hemp cultivation, rare cannabinoids, cannabis breeding
Industry4 codes
PRIMARYAFABALAJ
Seed Trait Licensing & IP Management (Licensing, freedom-to-operate)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)
SECONDARYAFABALAL
Digital Breeding & Bioinformatics Software (Breeding informatics, decision tools)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)
SECONDARYAFABALAF
Phenotyping Technologies & Services (Field/Controlled Environment)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)
SECONDARYAFAGAIAG
Biotechnology & Gene-Edited Trait Development
Agriculture & Food Production/Crop Farming/Seed Production & Plant Breeding (Seed Multiplication, Hybrid Seed, Certified Seed)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Patent Owners & Lessors6794
Product category
Cannabis Seed Genetics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Seed Sales
TypeOne Time License
Description

Commercial-scale sales of F1 hybrid cannabis and hemp seeds to cultivators. Seeds are sold through direct sales team, e-commerce platform (seeds.phylos.bio), and channel partners like ILGM. Also offers commercial bulk orders.

phylos.bio
2Rare Cannabinoid Ingredients (Natural Natural Brand)
TypeLicensing Royalties
Description

Consumer-facing ingredient brand commercializing patented naturally-derived rare cannabinoid genetics. Phylos Natural THCV varieties power high-quality supply chain of naturally-derived THCV through partnerships with growers, extractors, and consumer brands.

phylos.bio
3Variety Licensing
TypeLicensing Royalties
Description

In-licensing unique genetics from breeders for continued development and optimization, with fair compensation through licensing agreements.

phylos.bio
4Innovation Partnership Access
TypeLicensing Royalties
Description

Strategic partnerships providing priority access to genetics pipeline, exclusive rights to selected cultivars in specific markets, and co-development of seed-based production with cannabis operators like Organigram.

phylos.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Technology or R&D
Pricing details1 tier
1Seed products available through e-commerce (seeds.phylos.bio) with commercial bulk orders for larger cultivators
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Contact sales team at 503.206.6599 x 1 or via chat for commercial pricing. No public pricing listed on website.

phylos.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Natural Natural
Description

Consumer-facing ingredient brand commercializing patented, naturally-derived rare cannabinoid genetics including THCV. Natural Natural THCV varieties power a high-quality supply chain of naturally-derived THCV products.

ca.investing.com
+3 more records
Core offering1 text field

Phylos develops and sells premium F1 hybrid cannabis and hemp seeds (Production-Ready Seeds, Elite Seeds, AutoCBD, and autoflower varieties) using proprietary marker-assisted selection and DNA genotyping technology to deliver clone-quality uniformity from seed. The company also commercializes naturally-derived rare cannabinoid genetics (Phylos Natural THCV / Natural Natural brand) under licensing partnerships with consumer brands across multiple U.S. states and Canada.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 55% reduction in labor hours with autoflower seeds due to no transplanting, minimal pruning, and streamlined scouting
+9 more records
Product overview1 text field

Phylos is a cannabis genetics company operating as a unified platform anchored by its Production-Ready Seed core product: premium, phenotypically stable, fully-feminized F1 hybrid seed lines for cannabis and hemp. The portfolio spans three tiers — Elite Seeds (for controlled environments), standard Feminized Seeds, and Autoflower Seeds (both THC and AutoCBD hemp) — all supported by rigorous quality testing. A parallel product line centers on THCV rare cannabinoids, anchored by the Natural Natural ingredient brand (Get Sh!t Done, Joyride, Powerhouse) backed by IRB-proven clinical efficacy. Supporting infrastructure includes the Phylos Galaxy genetic visualization platform, the Innovation Partner Program for strategic genetics licensing, and specialized Genotype and Plant Sex Tests. The platform is science-driven, using genetic marker technology to select plants at the seedling stage, enabling rapid breeding cycles and trait-specific optimization across seed and cannabinoid products.

Product and service8 records
1Production-Ready F1 Hybrid Cannabis Seeds
CategoryCannabis Seed Genetics
Description

Phylos' flagship offering: premium, phenotypically stable, fully-feminized F1 hybrid cannabis seed lines engineered to deliver clone-quality uniformity in flower quality, potency, vigor, and yield for commercial-scale cultivation.

2Elite Seeds
CategoryCannabis Seed Genetics
Description

High-potency, production-ready F1 hybrid seed varieties designed for controlled environments (indoor and greenhouse), with stress tolerance, HLVd-resistance, reduced hermaphroditism, and yields that outperform clones at lower production cost.

3AutoCBD F1 Hybrid Hemp Seeds
CategoryHemp Seed Genetics
Description

Flagship autoflower hemp seed variety designed for outdoor and mixed-light cultivation with shortened maturation times and extensive germplasm validation. First hemp seed released by Phylos.

4Phylos Natural THCV Varieties (GSD, Joyride, Powerhouse)
CategoryRare Cannabinoid Genetics
Description

Naturally-derived THCV cannabis varieties bred through modern plant breeding: Get Sh!t Done (GSD, 15.2% THCV), Joyride (14.5% THCV), and Powerhouse (19.8% THCV). First cannabis varieties with naturally-occurring high-THCV content, clinically validated through an IRB-approved People Science study.

5Natural Natural Ingredient Brand
CategoryRare Cannabinoid Ingredients
Description

Consumer-facing ingredient brand powered by Phylos' patented naturally-derived rare cannabinoid genetics, supplying THCV ingredients and licensing to wholesale cultivators and consumer brands (Camino, Lost Farms, Heavy Hitters, Kanha, Airgraft, Garden Society, SHRED, Trailblazer, and others) across 10+ U.S. markets and Canada.

6Phylos Galaxy
CategoryGenomic Data Platform
Description

Interactive 3D genetic visualization and benchmarking platform featuring thousands of industrial hemp and cannabis DNA samples from 80+ countries, mapped to six sub-populations. Provides Genotype Reports showing identical clone matches, relational information, and breeding potential for growers, breeders, and researchers.

7Genotype Test
CategoryGenomic Testing
Description

Genomic testing service that validates cannabis and hemp strains by analyzing DNA at specific genomic points, generating genotype reports and assigning each variety a location within the Phylos Galaxy reference framework.

8Plant Sex Test
CategoryGenomic Testing
Description

Genomic testing service that identifies the male gene in cannabis plants at seedling stage, enabling growers and breeders to cull males early and improve operational efficiency.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-04-10
Description

Exclusive partnership bringing 15 new F1 hybrid strains to home growers across legal U.S. markets through ILGM's online platform. Partnership leverages Phylos cutting-edge technology and extensive genetic library.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-27
Description

Clinical research partnership conducting IRB-approved, double-blind study on THCV effects. Results demonstrated GSD significantly increased energy, activity, motivation, and well-being without munchies or fatigue.

3Wholesale THCV Partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-27
Description

Pacific Dutch Group and LEEF (CA); Ascend Wellness (IL, MA, NJ); The Pharm (AZ); Common Citizen (MI); Curio Wellness (MD); Schwazze (CO); Buddies (OR) - with expansion plans.

phylos.bio
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-27
Description

Yada Yada, Camino, Lost Farms, Heavy Hitters, Kanha, Airgraft, Garden Society (CA); SHRED, Trailblazer (Canada); HiDays (AZ); Tunnel Vision, Ozone (IL, MA, NJ); Good Day (MD); reV (MI); Kites, Buddies (OR); Moonlit Cannabis (WA).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-03
Description

Partnership to donate 1 million AutoCBD Hemp Seeds to BIPOC growers across the country, countering impact of war on drugs and building prosperity for disproportionately affected communities.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Partner in 1 million hemp seed donation initiative for BIPOC farmers, providing scientific expertise and germplasm.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Dedicated research and cultivation partner with 80,000 sq ft glasshouse facility. PPR focuses on sustainable practices including partnership with Energy Trust of Oregon, Portland General Electric, and CLEAResult. Achieved 36% reduction in total energy use.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-01-01
Description

Partnership with world's leading sequencing company to develop first cannabis genotyping array generating 50,000 unique data points per plant.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Front Range Biosciences
TypeDirect peer
Description

Front Range Biosciences is a direct competitor in cannabis and hemp genetics, specializing in tissue culture propagation and disease-clean planting stock for cultivators. Both companies target commercial cannabis operators with science-driven genetics solutions and emphasize HLVd-free, uniform plant material.

TypeDirect peer
Description

Trait Biosciences is a cannabis biotechnology company developing proprietary cannabinoid genetics and seed-based production technologies. Like Phylos, Trait pursues IP-driven cannabis and hemp genetics with licensing and trait development as core revenue models.

TypeBroad incumbent
Description

Canopy Growth is a large multi-state cannabis operator with internal genetics and breeding programs. While primarily a cultivator/retailer, its scale and capital could enable it to develop or acquire F1 hybrid seed technology comparable to Phylos.

TypeBroad incumbent
Description

Aurora Cannabis is a vertically integrated cannabis producer with significant cultivation footprint and internal breeding operations. It operates across Canadian and international markets where Phylos has exclusivity deals via Organigram, making it an indirect competitor for global genetics supply.

TypeBroad incumbent
Description

Cresco Labs is a U.S. multi-state cannabis operator with cultivation at scale and proprietary genetics. Its capital base and scale make it a potential acquirer or competitor to Phylos in supplying premium seeds to operators.

TypeOthers
Description

Organigram is both Phylos' largest strategic investor ($10M debt-funded) and a customer via the Innovation Partner Program. While not a genetics competitor, Organigram represents Phylos' most concentrated single-counterparty exposure and is a vertically integrated cannabis operator.

TypeBroad incumbent
Description

Cronos Group is a Canadian-licensed cannabis producer with international operations and prior investment in cannabinoid biotechnology (including a fermentation partnership with Ginkgo Bioworks). Its scale and biotech orientation make it a comparable cannabis operator.

TypeEmerging player
Description

Demetrix is a cannabinoid biotech company using fermentation to produce rare cannabinoids (initially CBG) at scale. While Demetrix pursues synthetic-biology rather than plant-breeding approaches, both companies compete in supplying rare cannabinoid ingredients to consumer brands.

TypeBroad incumbent
Description

Royal Queen Seeds is a leading European cannabis seed bank with global distribution. While more retail/home-grower focused than Phylos' commercial Elite Seeds, it is comparable as a branded cannabis seed company operating across multiple legal markets.

TypeOthers
Description

Hawthorne is Scotts Miracle-Gro's cannabis-focused cultivation supplies subsidiary, distributing nutrients, lighting, and genetics inputs to commercial growers. While not a direct seed-genetics competitor, Hawthorne's distribution scale and capital backing make it a potential channel or competitor in cannabis cultivation inputs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phylos

Cannabis Seed Geneticsphylos.bio

Phylos Bioscience is a Portland-based cannabis and hemp genetics company founded in 2014 that develops F1 hybrid seeds, rare cannabinoid (THCV) genetics, and genomic tools for commercial cultivators, extraction brands, consumer product companies, and home growers. Revenue is generated through seed sales, branded ingredient licensing, and strategic Innovation Partner agreements.

What Phylos does

Phylos Bioscience is a Portland, Oregon-based cannabis and hemp genetics company founded in 2014 that develops F1 hybrid seeds, rare cannabinoid (THCV) genetics, and genomic tools for commercial cultivators, extraction operators, consumer brands, and home growers. The company's core product is its Production-Ready Seed platform — fully-feminized, phenotypically stable F1 hybrid lines developed through marker-assisted selection and supported by an Illumina-partnered genotyping array that generates 50,000+ data points per plant. Phylos also operates the Phylos Galaxy, a 3D visualization tool containing genetic samples from 80+ countries mapped to six sub-populations, and a parallel rare-cannabinoid program anchored by the Natural Natural brand (THCV-dominant varieties GSD, Joyride, Powerhouse) with efficacy validated by an IRB-approved People Science clinical study.

The company monetizes through four primary revenue streams: direct and channel-based seed sales (commercial cultivators via enterprise sales plus home growers through an exclusive ILGM partnership), licensing of rare cannabinoid genetics to consumer brands, variety licensing for in-licensed genetics, and the Innovation Partner Program providing strategic operators like Organigram Global with priority access to the genetics pipeline and territorial exclusivity in Canada, Australia, UK, Germany, and Israel. Total committed capital includes $10M in senior secured convertible loans from Organigram (maturity May 2028), a $7.6M 2022 round led by Merida Capital Holdings with Accomplice and Entourage Effect Capital, and a 2024 SEC exempt offering of up to $4M. Pricing is not publicly disclosed; commercial seed pricing is quote-based while consumer sales flow through e-commerce at seeds.phylos.bio.

Phylos serves commercial cannabis cultivators, licensed hemp growers, extraction companies, and home growers across more than 10 U.S. states and five international markets. The company employs 51-100 staff including geneticists, breeders, and data scientists, operates an 80,000 ft² R&D glasshouse facility in partnership with Progressive Plant Research (a jointly controlled subsidiary), and has published proprietary genetic markers for stress tolerance, hermaphroditism resistance, autoflowering behavior (PRR37/PRR3 locus on chromosome 1), and washability (markers on chromosomes 6 and 7) — establishing a defensible position at the intersection of seed genetics and computational genomics for cannabis.

Phylos firmographics

Firmographics
Name
Phylos
Legal name
Phylos Bioscience, Inc.
Website
https://phylos.bio
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Phylos Bioscience is a Portland-based cannabis and hemp genetics company founded in 2014 that develops F1 hybrid seeds, rare cannabinoid (THCV) genetics, and genomic tools for commercial cultivators, extraction brands, consumer product companies, and home growers. Revenue is generated through seed sales, branded ingredient licensing, and strategic Innovation Partner agreements.
Ownership category
akta.pro rank

Phylos industry classification

Industry
Product category
Cannabis Seed Genetics
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Patent Owners & Lessors (6794)
akta.pro industry
PRIMARYAFABALAJ
Seed Trait Licensing & IP Management (Licensing, freedom-to-operate)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)
SECONDARYAFABALAL
Digital Breeding & Bioinformatics Software (Breeding informatics, decision tools)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)
SECONDARYAFABALAF
Phenotyping Technologies & Services (Field/Controlled Environment)
Agriculture & Food Production/Agricultural Inputs & Agrochemicals/Seed Technologies (Genetic Engineering & Trait Development)
SECONDARYAFAGAIAG
Biotechnology & Gene-Edited Trait Development
Agriculture & Food Production/Crop Farming/Seed Production & Plant Breeding (Seed Multiplication, Hybrid Seed, Certified Seed)

Keywords

  • Cannabis seed genetics
  • F1 hybrid seeds
  • Hemp cultivation
  • Rare cannabinoids
  • Cannabis breeding

Where Phylos is headquartered

Location

Headquarters

HQ city
Portland
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Phylos business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D

Revenue model

  1. Seed Sales: Commercial-scale sales of F1 hybrid cannabis and hemp seeds to cultivators. Seeds are sold through direct sales team, e-commerce platform (seeds.phylos.bio), and channel partners like ILGM. Also offers commercial bulk orders.
  2. Rare Cannabinoid Ingredients (Natural Natural Brand): Consumer-facing ingredient brand commercializing patented naturally-derived rare cannabinoid genetics. Phylos Natural THCV varieties power high-quality supply chain of naturally-derived THCV through partnerships with growers, extractors, and consumer brands.
  3. Variety Licensing: In-licensing unique genetics from breeders for continued development and optimization, with fair compensation through licensing agreements.
  4. Innovation Partnership Access: Strategic partnerships providing priority access to genetics pipeline, exclusive rights to selected cultivars in specific markets, and co-development of seed-based production with cannabis operators like Organigram.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goSeed products available through e-commerce (seeds.phylos.bio) with commercial bulk orders for larger cultivators

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Phylos product offering

Product offering

Core offering

Phylos develops and sells premium F1 hybrid cannabis and hemp seeds (Production-Ready Seeds, Elite Seeds, AutoCBD, and autoflower varieties) using proprietary marker-assisted selection and DNA genotyping technology to deliver clone-quality uniformity from seed. The company also commercializes naturally-derived rare cannabinoid genetics (Phylos Natural THCV / Natural Natural brand) under licensing partnerships with consumer brands across multiple U.S. states and Canada.

Product overview

Phylos is a cannabis genetics company operating as a unified platform anchored by its Production-Ready Seed core product: premium, phenotypically stable, fully-feminized F1 hybrid seed lines for cannabis and hemp. The portfolio spans three tiers — Elite Seeds (for controlled environments), standard Feminized Seeds, and Autoflower Seeds (both THC and AutoCBD hemp) — all supported by rigorous quality testing. A parallel product line centers on THCV rare cannabinoids, anchored by the Natural Natural ingredient brand (Get Sh!t Done, Joyride, Powerhouse) backed by IRB-proven clinical efficacy. Supporting infrastructure includes the Phylos Galaxy genetic visualization platform, the Innovation Partner Program for strategic genetics licensing, and specialized Genotype and Plant Sex Tests. The platform is science-driven, using genetic marker technology to select plants at the seedling stage, enabling rapid breeding cycles and trait-specific optimization across seed and cannabinoid products.

Differentiator

Problem solved

Functional benefit

Brands

  • Natural Natural: Consumer-facing ingredient brand commercializing patented, naturally-derived rare cannabinoid genetics including THCV. Natural Natural THCV varieties power a high-quality supply chain of naturally-derived THCV products.
  • Production-Ready Seed
  • Phylos Natural THCV
  • Phylos Galaxy

Products and services

  • Production-Ready F1 Hybrid Cannabis Seeds Phylos' flagship offering: premium, phenotypically stable, fully-feminized F1 hybrid cannabis seed lines engineered to deliver clone-quality uniformity in flower quality, potency, vigor, and yield for commercial-scale cultivation.
  • Elite Seeds High-potency, production-ready F1 hybrid seed varieties designed for controlled environments (indoor and greenhouse), with stress tolerance, HLVd-resistance, reduced hermaphroditism, and yields that outperform clones at lower production cost.
  • AutoCBD F1 Hybrid Hemp Seeds Flagship autoflower hemp seed variety designed for outdoor and mixed-light cultivation with shortened maturation times and extensive germplasm validation. First hemp seed released by Phylos.
  • Phylos Natural THCV Varieties (GSD, Joyride, Powerhouse) Naturally-derived THCV cannabis varieties bred through modern plant breeding: Get Sh!t Done (GSD, 15.2% THCV), Joyride (14.5% THCV), and Powerhouse (19.8% THCV). First cannabis varieties with naturally-occurring high-THCV content, clinically validated through an IRB-approved People Science study.
  • Natural Natural Ingredient Brand Consumer-facing ingredient brand powered by Phylos' patented naturally-derived rare cannabinoid genetics, supplying THCV ingredients and licensing to wholesale cultivators and consumer brands (Camino, Lost Farms, Heavy Hitters, Kanha, Airgraft, Garden Society, SHRED, Trailblazer, and others) across 10+ U.S. markets and Canada.
  • Phylos Galaxy Interactive 3D genetic visualization and benchmarking platform featuring thousands of industrial hemp and cannabis DNA samples from 80+ countries, mapped to six sub-populations. Provides Genotype Reports showing identical clone matches, relational information, and breeding potential for growers, breeders, and researchers.
  • Genotype Test Genomic testing service that validates cannabis and hemp strains by analyzing DNA at specific genomic points, generating genotype reports and assigning each variety a location within the Phylos Galaxy reference framework.
  • Plant Sex Test Genomic testing service that identifies the male gene in cannabis plants at seedling stage, enabling growers and breeders to cull males early and improve operational efficiency.

Quantifiable outcome

  • 55% reduction in labor hours with autoflower seeds due to no transplanting, minimal pruning, and streamlined scouting
  • +9 more outcomes

Companies that use Phylos

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles3 records

Phylos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature9 records

Phylos partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • I Love Growing Marijuana (ILGM)coreChannel Partner/ Reseller/ Distributor · 10 April 2024Exclusive partnership bringing 15 new F1 hybrid strains to home growers across legal U.S. markets through ILGM's online platform. Partnership leverages Phylos cutting-edge technology and extensive genetic library.
  • People SciencecoreStrategic or Co-development Partner · 27 February 2024Clinical research partnership conducting IRB-approved, double-blind study on THCV effects. Results demonstrated GSD significantly increased energy, activity, motivation, and well-being without munchies or fatigue.
  • Wholesale THCV PartnerscoreChannel Partner/ Reseller/ Distributor · 27 February 2024Pacific Dutch Group and LEEF (CA); Ascend Wellness (IL, MA, NJ); The Pharm (AZ); Common Citizen (MI); Curio Wellness (MD); Schwazze (CO); Buddies (OR) - with expansion plans.
  • Brand Partners (Natural Natural)coreChannel Partner/ Reseller/ Distributor · 27 February 2024Yada Yada, Camino, Lost Farms, Heavy Hitters, Kanha, Airgraft, Garden Society (CA); SHRED, Trailblazer (Canada); HiDays (AZ); Tunnel Vision, Ozone (IL, MA, NJ); Good Day (MD); reV (MI); Kites, Buddies (OR); Moonlit Cannabis (WA).
  • National Black Farmers AssociationminorStrategic or Co-development Partner · 3 November 2021Partnership to donate 1 million AutoCBD Hemp Seeds to BIPOC growers across the country, countering impact of war on drugs and building prosperity for disproportionately affected communities.
  • Oregon State University (Global Hemp Innovation Center)minorStrategic or Co-development Partner · 1 November 2021Partner in 1 million hemp seed donation initiative for BIPOC farmers, providing scientific expertise and germplasm.
  • Progressive Plant Research (PPR)coreStrategic or Co-development Partner · 1 January 2019Dedicated research and cultivation partner with 80,000 sq ft glasshouse facility. PPR focuses on sustainable practices including partnership with Energy Trust of Oregon, Portland General Electric, and CLEAResult. Achieved 36% reduction in total energy use.
  • IlluminacoreTechnology or Integration · 1 January 2018Partnership with world's leading sequencing company to develop first cannabis genotyping array generating 50,000 unique data points per plant.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Phylos competitors and assessment

Company assessment

Direct peers

  • Front Range Biosciences: Front Range Biosciences is a direct competitor in cannabis and hemp genetics, specializing in tissue culture propagation and disease-clean planting stock for cultivators. Both companies target commercial cannabis operators with science-driven genetics solutions and emphasize HLVd-free, uniform plant material.
  • Trait Biosciences: Trait Biosciences is a cannabis biotechnology company developing proprietary cannabinoid genetics and seed-based production technologies. Like Phylos, Trait pursues IP-driven cannabis and hemp genetics with licensing and trait development as core revenue models.

Broad incumbents

  • Canopy Growth Corporation: Canopy Growth is a large multi-state cannabis operator with internal genetics and breeding programs. While primarily a cultivator/retailer, its scale and capital could enable it to develop or acquire F1 hybrid seed technology comparable to Phylos.
  • Aurora Cannabis: Aurora Cannabis is a vertically integrated cannabis producer with significant cultivation footprint and internal breeding operations. It operates across Canadian and international markets where Phylos has exclusivity deals via Organigram, making it an indirect competitor for global genetics supply.
  • Cresco Labs: Cresco Labs is a U.S. multi-state cannabis operator with cultivation at scale and proprietary genetics. Its capital base and scale make it a potential acquirer or competitor to Phylos in supplying premium seeds to operators.
  • Cronos Group: Cronos Group is a Canadian-licensed cannabis producer with international operations and prior investment in cannabinoid biotechnology (including a fermentation partnership with Ginkgo Bioworks). Its scale and biotech orientation make it a comparable cannabis operator.
  • Royal Queen Seeds: Royal Queen Seeds is a leading European cannabis seed bank with global distribution. While more retail/home-grower focused than Phylos' commercial Elite Seeds, it is comparable as a branded cannabis seed company operating across multiple legal markets.

Others

  • Organigram Global: Organigram is both Phylos' largest strategic investor ($10M debt-funded) and a customer via the Innovation Partner Program. While not a genetics competitor, Organigram represents Phylos' most concentrated single-counterparty exposure and is a vertically integrated cannabis operator.
  • Hawthorne Gardening Company (Scotts Miracle-Gro): Hawthorne is Scotts Miracle-Gro's cannabis-focused cultivation supplies subsidiary, distributing nutrients, lighting, and genetics inputs to commercial growers. While not a direct seed-genetics competitor, Hawthorne's distribution scale and capital backing make it a potential channel or competitor in cannabis cultivation inputs.

Emerging players

  • Demetrix: Demetrix is a cannabinoid biotech company using fermentation to produce rare cannabinoids (initially CBG) at scale. While Demetrix pursues synthetic-biology rather than plant-breeding approaches, both companies compete in supplying rare cannabinoid ingredients to consumer brands.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Phylos social profiles

Digital presence

Phylos compliance and trust

Trust signal

Compliance1 record

Phylos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phylos leadership team

Management profile

Number of profiles

Profiles12 records

Phylos subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Phylos funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phylos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phylos

What does Phylos do?

Phylos develops and sells premium F1 hybrid cannabis and hemp seeds (Production-Ready Seeds, Elite Seeds, AutoCBD, and autoflower varieties) using proprietary marker-assisted selection and DNA genotyping technology to deliver clone-quality uniformity from seed. The company also commercializes naturally-derived rare cannabinoid genetics (Phylos Natural THCV / Natural Natural brand) under licensing partnerships with consumer brands across multiple U.S. states and Canada.

Is Phylos a public or private company?

Phylos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Phylos founded?

Phylos was founded in 2014. It employs 11 to 50 people.

Where is Phylos based?

Phylos is headquartered in Portland, United States, in the North America region.

How does Phylos make money?

Four revenue lines are on record. Seed Sales are the primary driver. The others are rare Cannabinoid Ingredients (Natural Natural Brand), variety Licensing and innovation Partnership Access.

Who are Phylos's main competitors?

Direct peers on record are Front Range Biosciences and Trait Biosciences. Broad incumbents are Canopy Growth Corporation, Aurora Cannabis, Cresco Labs, Cronos Group and Royal Queen Seeds. Others are Organigram Global and Hawthorne Gardening Company (Scotts Miracle-Gro). Demetrix is listed as an emerging player.

Does Phylos have an API?

No public API is recorded for Phylos.

What industry is Phylos in?

Phylos's product category is Cannabis Seed Genetics. Its primary akta.pro industry code is AFABALAJ, Seed Trait Licensing & IP Management (Licensing, freedom-to-operate), with a secondary code of AFABALAL, Digital Breeding & Bioinformatics Software (Breeding informatics, decision tools). Its NAICS code is 325411 and its SIC code is 6794.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StratCannOrganigram extends innovation investment with PhylosOrganigram Global Inc. announced an expansion of its investment in cannabis genetics company Phylos Bioscience Inc. on December 31, 2025, including an amended loan and product agreement. The expanded deal gives Organigram priority access to Phylos’ genetics and exclusivity in multiple international markets, supporting its growth strategy. The investment aims to enhance Organigram’s cannabis cultivation through genetically bred seed innovation and differentiation.Investing.comOrganigram expands Phylos partnership to secure cannabis genetics By Investing.comOrganigram Global Inc. announced the expansion of its innovation partnership with Phylos Bioscience Inc., committing an additional US$3 million to secure long-term access to cannabis genetics, bringing total investment to US$10 million with maturity on May 25, 2028. The agreement provides Organigram with priority access to Phylos' autoflower genetics pipeline, including 30 new genetics delivered twice annually through 2030, plus five-year exclusive rights for selected cannabis genetics in Canada, Australia, the UK, Germany, and Israel. The partnership aims to strengthen Organigram's seed-based cultivation strategy, which the company states provides consistency, scalability, and economic benefits for both recreational and medical markets.Investing.comOrganigram expands Phylos partnership to secure cannabis genetics By Investing.comOrganigram Global Inc. announced an expansion of its partnership with Phylos Bioscience Inc., investing an additional US$3 million to secure access to cannabis genetics and granting exclusive rights in international markets. The deal includes priority access to Phylos' genetics pipeline, supporting Organigram’s seed-based cultivation approach and enhancing its operational security. This expansion aims to strengthen Organigram’s market position and facilitate international growth.Business Wire BlogOrganigram Extends Innovation Investment with PhylosOrganigram Global Inc. has expanded its innovation investment in Phylos Bioscience Inc. with a US$3 million convertible loan advance, bringing the total loan principal to US$10 million. The amended agreement grants Organigram priority access to Phylos' autoflower genetics pipeline and five-year exclusive rights for selected cultivars in international markets through 2030. This strategic move aims to secure next-generation seed-based cannabis genetics to support Organigram's growth in recreational and medical sectors globally.Stock TitanOrganigram (OGI) expands Phylos seed-genetics deal to $10MOrganigram Global Inc. announced an expanded investment in Phylos Bioscience Inc., consolidating its existing investment with a new US$3 million advance for a combined total loan principal of US$10 million. The deal grants Organigram priority access to Phylos' autoflower genetics pipeline, including five-year exclusivity on chosen cultivars across international markets including Canada, Australia, the UK, Germany, and Israel, with 30 new genetics delivered twice annually through 2030. Phylos CEO Ralph Risch stated that the investment allows Phylos to accelerate development of new traits and F1 hybrid seeds while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale.EIN PresswirePhylos Secures Strategic Investment from Organigram to Accelerate Cannabis Genetics PlatformPhylos Bioscience announced a strategic investment from Organigram Holdings Inc., a leading licensed cannabis producer, to accelerate development of its cannabis genetics platform. Through this investment, Organigram gains priority access to selected F1 hybrid genetics while Phylos advances its breeding program focused on yield, disease resistance, and production efficiency. The expanded partnership reflects a shared long-term view that cannabis production is moving toward modern agricultural systems built on predictable, data-driven genetics.MorningstarToronto Stocks Edge Lower; Organigram Increases Investment in Phylos BioscienceOrganigram Global increased its investment by $3 million in cannabis genetics company Phylos Bioscience, bringing its consolidated investment to $10 million in the form of a loan agreement. The investment grants Organigram priority access to Phylos Bioscience's cannabis plant seeds. The announcement came on Wednesday as Toronto stocks traded lower, with the S&P/TSX Composite Index falling 0.3% to 31759.09, while Organigram shares rose 0.2% to C$2.33.MarketScreenerToronto Stocks Edge Lower; Organigram Increases Investment in Phylos BioscienceToronto stocks closed lower on December 31, 2025, the final trading day of the year, with the S&P/TSX Composite Index falling 0.3% to 31,759.09. Organigram Global announced it increased its investment by $3 million in cannabis genetics company Phylos Bioscience, bringing its consolidated investment to $10 million, in exchange for priority access to cannabis plant seeds. The TSX will remain closed on January 1 for New Year's Day.TipranksOrganigram Deepens Phylos Partnership to Secure Long-Term Cannabis Genetics EdgeOrganigram Global Inc. has expanded its innovation partnership with cannabis genetics specialist Phylos Bioscience Inc. through an amended loan and product agreement, providing an additional US$3 million advance that brings the total loan commitment to US$10 million. The deal secures Organigram priority access to Phylos' autoflower genetics pipeline with 30 new genetics delivered twice annually through 2030, along with five-year exclusive rights to selected autoflower cultivars in Canada, Australia, the UK, Germany, and Israel. The agreement positions Organigram as the first mover deploying scientifically bred F1 hybrid seeds at commercial scale, giving it an economic and competitive edge in both recreational and medical cannabis markets.HightimesHow Genomics is Shaping the Future of Cannabis BreedingGenetic sequencing and marker-assisted breeding are transforming the cannabis industry by enabling targeted cultivar development for traits like yield, potency, and disease resistance. Companies such as Phylos Bioscience and Medicinal Genomics are leading this shift through genomic mapping and microbiome research, countering earlier fears of corporate monopolization seen in other sectors.